CTLA4 and pachyonychia congenita: In this vein, there is a phase II trial (NCT04156087) of patients with non-resectable PC to undergo minimally invasive MWA in combination with a CTLA-4 mAb, a PD-L1 mAb, and adjuvant gemcitabine.